Crossmark

614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0614

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Routy, Bertrand

Lenehan, John

Daisley, Brendan

Messaoudene, Meriem

Al, Kait

Richard, Corentin

Miller, Wilson

Jamal, Rahima

Ernst, Scott

Logan, Diane

Belanger, Karl

Martinez-Gili, Laura

Mullish, Benjamin

Takis, Panteleimon

Samayoa, Cecilia Hermosilla

Ninkov, Marina

Parvathy, Seema Nair

Lambert, Caroline

Elkrief, Arielle

Lapointe, Rejean

Haeryfar, Mansour

Burton, Jeremy

Silverman, Michael

Maleki, Saman
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03772899 at ClinicalTrials.gov

Documents that mention this clinical trial

Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial
https://doi.org/10.1136/jitc-2025-012659

614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
https://doi.org/10.1136/jitc-2022-sitc2022.0614

Document is current

Any future updates will be listed below